接受铂类治疗的卵巢透明细胞癌与浆液性癌患者的无进展生存期和总生存期评估:一项NRG肿瘤学/妇科肿瘤组经验
本研究回顾了12项前瞻性随机GOG方案中FIGO I-IV期上皮性卵巢癌患者数据,比较卵巢透明细胞癌(OCCC)与浆液性癌(SOC)的预后差异。共10803例入组,9531例符合条件并接受铂类治疗,其中OCCC 544例(6%),SOC 7054例(74%)。早期(I-II期)OCCC的PFS显著优于SOC;晚期(III、IV期)OCCC的PFS和OS均更差,OS HR=1.66(1.43, 1.91; p<0.001),调整后OS HR=1.53(1.33, 1.76; p<0.001)。
要点
- 早期(I-II期)卵巢透明细胞癌的PFS显著优于浆液性癌。
- 晚期(III、IV期)卵巢透明细胞癌的PFS和OS均劣于浆液性癌,调整后OS HR=1.53(1.33, 1.76; p<0.001)。
- 早期病例中,每周紫杉醇巩固治疗对比观察对PFS的治疗效应因组织学类型而异(p=0.048)。
核心结论
- OCCC组织学在早期疾病中比SOC更常见;调整预后因素后,早期OCCC的PFS优于SOC,但晚期OCCC与OS降低显著相关,且治疗效应受组织学影响。
研究设计与样本
- 回顾性分析12项前瞻性随机GOG方案中FIGO I-IV期上皮性卵巢癌患者数据,采用比例风险模型比较OCCC与SOC的PFS和OS。
- 共10803例入组,9531例符合条件、可评估并接受铂类治疗,其中OCCC 544例(6%),SOC 7054例(74%),其他组织学类型1933例(20%)未进一步纳入分析。
主要发现
- 早期(I-II期)患者中,OCCC的PFS显著优于SOC。
- 晚期(III、IV期)患者中,OCCC的PFS和OS均劣于SOC,OS HR=1.66(1.43, 1.91; p<0.001)。
- 调整年龄并按方案和治疗臂、分期、体能状态及种族分层后,OCCC的OS显著降低,HR=1.53(1.33, 1.76; p<0.001)。
- 早期病例中,每周紫杉醇巩固治疗对比观察对PFS的治疗效应在OCCC与SOC间存在显著差异(p=0.048)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We examined disparities in prognosis between patients with ovarian clear cell carcinoma (OCCC) and serous epithelial ovarian cancer (SOC). METHODS: We reviewed data from FIGO stage I-IV epithelial ovarian cancer patients who participated in 12 prospective randomized GOG protocols. Proportional hazards models were used to compare progression-free survival (PFS) and overall survival (OS) by cell type (clear cell versus serous). RESULTS: There were 10,803 patients enrolled, 9531 were eligible, evaluable and treated with platinum, of whom 544 (6%) had OCCC, 7054 (74%) had SOC, and 1933 (20%) had other histologies and are not included further. In early stage (I-II) patients, PFS was significantly better in OCCC than in SOC patients. For late stage (III, IV) patients, OCCC had worse PFS and OS compared to SOC, OS HR=1.66 (1.43, 1.91; p<0.001). After adjusting for age and stratifying by protocol and treatment arm, stage, performance status, and race, OCCC had a significantly decreased OS, HR=1.53 (1.33, 1.76; p<0.001). In early stage cases, there was a significantly decreased treatment effect on PFS for consolidative therapy with weekly Paclitaxel versus observation in OCCC compared to SOC (p=0.048). CONCLUSIONS: This is one of the largest analyses to date of OCCC treated on multiple cooperative group trials. OCCC histology is more common than SOC in early stage disease. When adjusted for prognostic factors, in early stage patients, PFS was better for OCCC than for SOC; however, in late-stage patients, OCCC was significantly associated with decreased OS. Finally, treatment effect was influenced by histology.
引用
- Oliver KE, Brady WE, Birrer M, et al. An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience. Gynecol Oncol. 2017. PMID: 28807367. doi:10.1016/j.ygyno.2017.08.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。